Literature DB >> 7689966

Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.

D Collen1, B Van Hoef, B Schlott, M Hartmann, K H Gührs, H R Lijnen.   

Abstract

The molecular basis of the marked interspecies variability in the response of plasma fibrinolytic systems to activation by streptokinase (SK) or recombinant staphylokinase (STAR) was studied using highly purified plasminogens and alpha 2-antiplasmins from five representative species (man, baboon, rabbit, dog and cow). Human plasminogen reacted rapidly and stoichiometrically with both SK and STAR to yield potent plasminogen activators (catalytic efficiencies, kcat/Km, of 1.0 microM-1 x s-1 and 0.3 microM-1 x s-1, respectively). The complex with SK was insensitive to alpha 2-antiplasmin, which, however, rapidly inhibited the complex with STAR (second-order rate constant, k1,app of 8 x 10(6) M-1 x s-1). In a system composed of a 0.06-ml 125I-fibrin-labeled plasma clot submerged in 0.30 ml plasma, both SK and STAR had potent fibrinolytic properties, causing 50% clot lysis in 2 h (EC50), with 120 nM and 13 nM, respectively. Clot lysis with SK was non-fibrin specific (residual fibrinogen < 10%), whereas lysis with STAR was highly fibrin specific (residual fibrinogen 76%). Canine plasminogen reacted avidly with SK, but SK was rapidly degraded; it reacted rapidly and quantitatively with STAR to form a potent plasminogen-activating complex (kcat/Km of 0.4 microM-1 x s-1) which was sensitive to neutralization by alpha 2-antiplasmin (k1,app of 6 x 10(5) M-1 x s-1). In a canine plasma milieu, SK was relatively potent (EC50 200 nM) and fibrin specific, whereas STAR was very potent (EC50 1.3 nM) but poorly fibrin specific. Baboon and rabbit plasminogen did not form stable stoichiometric complexes with SK, but reacted stoichiometrically and quantitatively with STAR. The complexes with STAR, however, had low catalytic efficiencies for the activation of their autologous plasminogens (kcat/Km 0.02 microM-1 x s-1) and reacted more slowly with alpha 2-antiplasmin (k1,app 5-10 x 10(5) M-1 x s-1). Bovine plasminogen was virtually unreactive towards both SK and STAR as well as to their complexes with human plasminogen, as monitored by measurement of the initial activation rates. The resistance to fibrinogen degradation with STAR observed in the human system could be transferred to the canine system by reconstituting canine plasma, depleted of plasminogen and alpha 2-antiplasmin, with the human proteins. Conversely, the sensitivity to fibrinogen degradation of the canine system could be transferred to the human system by reconstituting depleted plasma with canine plasminogen and alpha 2-antiplasmin. It is concluded that the variability in the response of mammalian plasma fibrinolytic systems to activation with SK or STAR is determined mainly by the extent of complex formation of these compounds with plasminogen, by the catalytic efficiencies of the complexes for the activation of autologous plasminogen and by the rate of inhibition of these complexes by alpha 2-antiplasmin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689966     DOI: 10.1111/j.1432-1033.1993.tb18147.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  Identification through combinatorial random and rational mutagenesis of a substrate-interacting exosite in the gamma domain of streptokinase.

Authors:  Suman Yadav; Rachna Aneja; Prakash Kumar; Manish Datt; Sonali Sinha; Girish Sahni
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

2.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

Review 3.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

4.  Effects on human plasminogen conformation and activation rate caused by interaction with VEK-30, a peptide derived from the group A streptococcal M-like protein (PAM).

Authors:  Mariana Figuera-Losada; Marie Ranson; Martina L Sanderson-Smith; Mark J Walker; Francis J Castellino; Mary Prorok
Journal:  Biochim Biophys Acta       Date:  2010-02-10

5.  Function of the 90-loop (Thr90-Glu100) region of staphylokinase in plasminogen activation probed through site-directed mutagenesis and loop deletion.

Authors:  Govindan Rajamohan; Monika Dahiya; Shekhar C Mande; Kanak L Dikshit
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

Review 6.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

Review 7.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

Review 8.  Thrombolytic agents in development.

Authors:  M Verstraete; H R Lijnen; D Collen
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

9.  Structure-based antigenic epitope and PEGylation improve the efficacy of staphylokinase.

Authors:  Yanying Xu; Yueyuan Shi; Jianzhong Zhou; Wei Yang; Lei Bai; Shilei Wang; Xin Jin; Qiangsi Niu; Ailong Huang; Deqiang Wang
Journal:  Microb Cell Fact       Date:  2017-11-14       Impact factor: 5.328

Review 10.  Plasminogen-binding proteins as an evasion mechanism of the host's innate immunity in infectious diseases.

Authors:  Dolores A Ayón-Núñez; Gladis Fragoso; Raúl J Bobes; Juan P Laclette
Journal:  Biosci Rep       Date:  2018-10-02       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.